Posted by Michael Wonder on 30 Oct 2023
Egetis announces EMA validation of marketing authorisation application for Emcitate for the treatment of MCT8 deficiency
27 October 2023 - Egetis Therapeutics today announced that its marketing authorisation application to the EMA for Emcitate (tiratricol) for the treatment of MCT8 deficiency has been validated.
On 9 October 2023, Egetis announced the submission of the marketing authorisation application.
